Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Sintilimab in EGFR-mutant T790M-negative NSCLC
NCT03765775Phase 2Unknown
- Sponsor
- People's Hospital of Shijiazhuang
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, sintilimab in non-small cell lung cancer (NSCLC), sponsored by People's Hospital of Shijiazhuang. Status: unknown.
02
Drugs
anlotinibsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03765775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765775.